A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation
Ischemia and reperfusion damage contribute to early graft dysfunction and recipient’s death. Here the authors show the feasibility and safety of a non-ischemic heart preservation method for heart transplantation in a non-randomized trial.
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-06-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-16782-9 |
| Summary: | Ischemia and reperfusion damage contribute to early graft dysfunction and recipient’s death. Here the authors show the feasibility and safety of a non-ischemic heart preservation method for heart transplantation in a non-randomized trial. |
|---|---|
| ISSN: | 2041-1723 |